Yumanity Therapeutics
790 Memorial Drive, Suite 2C
Cambridge
Massachusetts
02139
United States
Tel: 617-409-5300
Website: http://yumanity.com/
Email: info@yumanity.com
About Yumanity Therapeutics
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the estimated patient population of 50 million people worldwide, this remains an area of tremendous unmet medical need with no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address illnesses such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company’s approach concentrates on correcting the cellular pathologies driven by misfolded proteins and the altered biology and phenotypes driving these diseases.
66 articles with Yumanity Therapeutics
-
Kineta Completes Reverse Merger with Yumanity Therapeutics
12/19/2022
Kineta, Inc., a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced the completion of its reverse merger with Yumanity Therapeutics, Inc.
-
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
12/5/2022
Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV.
-
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
11/14/2022
Yumanity Therapeutics, Inc. today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments.
-
Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.
11/10/2022
Yumanity Therapeutics, Inc. announced that the registration statement on Form S-4, relating to the previously announced asset sale to Janssen Pharmaceutica NV and merger with Kineta, Inc., has been declared effective by the U.S. Securities and Exchange Commission.
-
Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta
8/29/2022
Yumanity Therapeutics, Inc. announced the filing of a registration statement on Form S-4 with the U.S. Securities and Exchange Commission.
-
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
8/4/2022
Yumanity Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced financial results for the second quarter ended June 30, 2022, and provided an overview of the Company’s recent corporate developments.
-
Aslan partners with Johns Hopkins and Duke, Editas joins forces with Immatics, Yumanity (soon to be Kineta, Inc.) teams with Janssen, Serotiny & Janssen Biotech and Ginkgo and Novo Nordisk.
-
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
6/6/2022
Yumanity Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced it has entered into definitive agreements for two strategic transactions.
-
Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments
5/12/2022
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2022, and provided an overview of the Company’s recent corporate developments.
-
Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments
3/24/2022
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for full-year ended December 31, 2021 and provided an overview of the Company’s recent corporate developments.
-
Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring
2/17/2022
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, announced that it is exploring strategic alternatives with the goal of enhancing shareholder value.
-
In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its financial woes, including the possibility of selling or merging.
-
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 04, 2022
2/4/2022
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the grant to two employees of non-statutory stock options for the purchase of up to an aggregate of 6,000 shares of Yumanity’s common stock.
-
Clinical Catch-Up: January 17-21
1/24/2022
Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look. -
Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739
1/19/2022
Yumanity Therapeutics today announced that, in response to its IND application submitted in December 2021, it was notified via email by the U.S. Food and Drug Administration (FDA) that the FDA has placed a partial clinical hold on multidose clinical trials of YTX-7739.
-
The FDA issued the partial clinical hold order in response to the IND application Yumanity submitted in December last year. The company expects additional data on the directive within the next 30 days.
-
Yumanity’s Approach to Neurodegenerative Diseases Validated by Two External Collaborations
1/11/2022
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today provided an update on recent corporate developments.
-
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 05, 2022
1/5/2022
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the grant to an employee of non-statutory stock options for the purchase of up to an aggregate of 11,000 shares of Yumanity’s common stock.
-
Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference
1/4/2022
Yumanity Therapeutics announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, being held virtually January 10-13, 2022.
-
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 03, 2021
12/3/2021
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the grant to 1 employee of non-statutory stock options for the purchase of up to an aggregate of 2,000 shares of Yumanity’s common stock.